On-Demand Webinar: (Part 2 of 4) Medical Cannabis in People With HIV: What’s the Evidence

On-Demand Webinar: (Part 2 of 4) Medical Cannabis in People With HIV: What’s the Evidence

Jessica Merlin, MD, PhD, MBA

Release date: October 6, 2020
Expiration date: October 6, 2021
No longer available for CME credit

Overview

Assessment of Needs

Medical cannabis is now legal in the majority of US states. Most individuals seeking medical cannabis do so for pain, which is common in people with HIV (PWH), and there has been increasing interest in understanding the role of cannabis in reducing opioid prescribing and treating opioid use disorder. This talk will review the state of the science of medical cannabis for pain and opioid use and use disorder in PWH, and will provide evidence-based talking points for conversations with patients and colleagues.

This webinar is part 2 of the 4-part webinar series on pain and addiction:

Learning Objectives

Upon completion of this webinar, learners will be able to:

  • Explain the evidence base for using medical cannabis in people with HIV
  • Describe to patients and colleagues the benefits and risks of medical cannabis in people with HIV

Registration

Note: The IAS–USA acknowledges the importance of delivering the same high-quality education and resources to our audiences despite the challenging times we are experiencing due to the COVID-19 pandemic. In response, the implementation of a nominal fee to process the claim of CME and CE credits for webinars has been postponed.

Who Should Attend

This advanced webinar is designed for clinical decision makers who are actively involved in HIV care and research.

This activity is also relevant for registered nurses, PharmDs, and other health professionals.

Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”

Presenter

Dr Merlin has no relevant financial affiliations to disclose. (Updated 08/28/20)

Planner/Reviewer

Planner/Reviewer 1 has no relevant financial affiliations to disclose. (Updated 09/30/20)
Planner/Reviewer 2 has no relevant financial affiliations to disclose. (Updated 09/30/20)

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS

Gilead Sciences, Inc
Merck & Co, Inc
ViiV Healthcare

SILVER SUPPORTER

Janssen Therapeutics

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.

Course Materials

How to Claim Credit

  1. Start the Activity by clicking "START COURSE" located above.
    Please note that the "START COURSE" will no longer be visible once you clicked it once.
  2. Watch the webinar here.
  3. Return to this page and follow this link to the evaluation form.
  4. Once you complete the evaluation, you will be directed to the online claim form, where you will record the number of hours that you participated in this activity. You must be logged in to your IAS–USA profile to claim credit. Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.
  5. Your certificate will be available for you to print from your IAS–USA account immediately after you have submitted your claim form. To view your certificates, go to "My Activities" under your profile.